CAG方案在治疗中高危骨髓增生异常综合征患者中的应用效果

The Effect of CAG Regimen in the Treatment of Patients with Intermediate or High Risk Myelodysplastic Syndrome

目的:评价CAG方案在治疗中高危骨髓增生异常综合征(MDS)患者中的应用效果。方法:收集笔者所在医院2012年6月-2015年4月收治的38例MDS患者的临床资料,所有患者均应用CAG治疗方案(Acla+Ara-C+G-CSF),治疗后对临床疗效进行评价,并观察患者治疗过程中的不良反应发生情况。结果:本组38例患者均顺利完成1个疗程的治疗,治疗总有效率为76.3%,外周血中性粒细胞达到<0.5×109/L水平的平均时间为(6.2±0.5)d。治疗期间患者均出现不同程度的骨髓抑制,另有5例患者出现消化道反应,3例患者出现口腔溃疡。结论:CAG方案治疗中高危MDS患者的临床疗效好,安全性可靠,患者的耐受性较好,应在临床治疗中进一步推广使用。

Objective： To evaluate the effect of CAG regimen in the treatment of patients with intermediate or high risk myelodysplastic syndrome（MDS）.Method： The clinical data about 38 cases with intermediate or high risk myelodysplastie syndrome in our hospital from April 2012 to June 2015 were collected, all patients were accepted CAG regimen （Acla＋Ara-C＋G-CSF） treatment, clinical efficacy after treatment was evaluated, and the adverse reactions were observed.Result： In 38 patients the total effective rate was 76.3%, the average time of peripheral blood neutrophil reached 〈0.5 × 10^9/L was （6.2 ± 0.5）d.During the treatment, cases all had different levels of.bone marrow suppression, and another 5 cases had gastrointestinal reaction, 3 cases had oral ulcers.Conclusion： The clinical effect of CAG regimen in the treatment of patients with intermediate or high risk myelodysplastic syndrome is good, the regimen is safe and reliable, and the patient is well tolerated, so should be used in clinical treatment.